Dr. Whelan Discusses the MA.20 Trial's Survival Findings

Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings

Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, discusses the various survival benefits found in the NCIC-CTG MA.20 intergroup phase III trial that randomized 1832 breast cancer patients to receive either whole-breast irradiation (WBI) or WBI plus regional nodal irradiation (RNI). Patients that received both RNI and WBI saw a disease-free survival of nearly 90% but failed to meet the primary endpoint of overall survival.